MD Anderson and Replay announce FDA clearance of IND application for first-in-class PRAME-targeted TCR NK cell therapy for hematological malignancies
MD Anderson and Replay today announced FDA clearance of the Investigational New Drug application for a novel PRAME-targeting TCR NK cell therapy for AML and MDS.